Ivan Hyep Sells 18,244 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 18,244 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $18.22, for a total value of $332,405.68. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,648,368.10. The trade was a 11.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Price Performance

Shares of BCAX stock opened at $18.26 on Friday. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $28.09. The stock’s 50-day moving average is $12.36 and its 200 day moving average is $11.83. The company has a market cap of $997.18 million and a P/E ratio of -5.76.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.04. On average, analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth about $25,000. CWM LLC purchased a new position in shares of Bicara Therapeutics in the first quarter worth about $29,000. Legal & General Group Plc raised its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. Piper Sandler assumed coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target for the company. Finally, HC Wainwright lowered their price target on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.86.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.